Format

Send to

Choose Destination
Med Hypotheses. 2017 Feb;99:57-62. doi: 10.1016/j.mehy.2016.12.006. Epub 2016 Dec 22.

Huperzine A: A promising anticonvulsant, disease modifying, and memory enhancing treatment option in Alzheimer's disease.

Author information

1
F.M. Kirby Neurobiology Center, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
2
Biscayne Pharmaceuticals, Inc., Miami, FL, USA.
3
Department of Neurology, Beth Israel Deaconess Medical Center, and Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
4
F.M. Kirby Neurobiology Center, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: Alexander.Rotenberg@childrens.harvard.edu.

Abstract

Alzheimer's disease (AD) is the most frequent cause of dementia. Besides cognitive deterioration, patients with AD are prone to seizures - more than 20% of patients diagnosed with AD experience at least one unprovoked seizure and up to 7% have recurrent seizures. Although available antiepileptic drugs (AEDs) may suppress seizures in patients with AD, they may also worsen cognitive dysfunction and increase the risk of falls. On the basis of preclinical studies, we hypothesize that Huperzine A (HupA), a safe and potent acetylcholinesterase (AChE) inhibitor with potentially disease-modifying qualities in AD, may have a realistic role as an anticonvulsant in AD.

KEYWORDS:

Acetylcholinesterase; Alzheimer’s disease; Antiepileptic; Huperzine A; Nicotinic; Seizure; ppTMS

PMID:
28110700
DOI:
10.1016/j.mehy.2016.12.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center